223 related articles for article (PubMed ID: 15187994)
1. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Parra HS; Cavina R; Latteri F; Zucali PA; Campagnoli E; Morenghi E; Grimaldi GC; Roncalli M; Santoro A
Br J Cancer; 2004 Jul; 91(2):208-12. PubMed ID: 15187994
[TBL] [Abstract][Full Text] [Related]
2. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
[TBL] [Abstract][Full Text] [Related]
3. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Jänne PA; Gurubhagavatula S; Yeap BY; Lucca J; Ostler P; Skarin AT; Fidias P; Lynch TJ; Johnson BE
Lung Cancer; 2004 May; 44(2):221-30. PubMed ID: 15084387
[TBL] [Abstract][Full Text] [Related]
5. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
Suzuki T; Nakagawa T; Endo H; Mitsudomi T; Masuda A; Yatabe Y; Sugiura T; Takahashi T; Hida T
Lung Cancer; 2003 Oct; 42(1):35-41. PubMed ID: 14512185
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Han SW; Hwang PG; Chung DH; Kim DW; Im SA; Kim YT; Kim TY; Heo DS; Bang YJ; Kim NK
Int J Cancer; 2005 Jan; 113(1):109-15. PubMed ID: 15386420
[TBL] [Abstract][Full Text] [Related]
7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
10. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Razis E; Skarlos D; Briasoulis E; Dimopoulos M; Fountzilas G; Lambropoulos S; Rigatos S; Kopterides P; Efstathiou H; Tzamakou E; Bakoyannis C; Pectasides D; Makatsoris T; Varthalitis G; Papadopoulos S; Kosmidis P
Anticancer Drugs; 2005 Feb; 16(2):191-8. PubMed ID: 15655417
[TBL] [Abstract][Full Text] [Related]
11. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
12. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Blackledge G; Averbuch S
Br J Cancer; 2004 Feb; 90(3):566-72. PubMed ID: 14760365
[TBL] [Abstract][Full Text] [Related]
15. ZD1839 (Iressa) in non-small cell lung cancer.
Herbst RS; Kies MS
Oncologist; 2002; 7 Suppl 4():9-15. PubMed ID: 12202783
[TBL] [Abstract][Full Text] [Related]
16. Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Tang C; Gao H; Li X; Liu Y; Li J; Qin H; Wang W; Qu L; An J; Yang S; Liu X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):427-33. PubMed ID: 24401995
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Giaccone G; Iacona RB; Fandi A; Janas M; Ochs JS; Herbst RS; Johnson DH
J Cancer Res Clin Oncol; 2009 Mar; 135(3):467-76. PubMed ID: 18787840
[TBL] [Abstract][Full Text] [Related]
18. 'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Pao W; Miller VA; Kris MG
Semin Cancer Biol; 2004 Feb; 14(1):33-40. PubMed ID: 14757534
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
20. Extensive experience of disease control with gefitinib and the role of prognostic markers.
Cortes-Funes H; Soto Parra H
Br J Cancer; 2003 Dec; 89 Suppl 2(Suppl 2):S3-8. PubMed ID: 14661046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
